Quick Answer
Neumora Therapeutics, Inc. reported Total Assets of $191.05 million for fiscal year 2025.
Neumora Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $191.05M | -39.7% |
| 2024 | $316.97M | -36.1% |
| 2023 | $496.19M | +16.4% |
| 2022 | $426.23M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $177.83M | -49.6% | -20.5% |
| June 30, 2025 | $223.82M | -44.7% | -12.8% |
| March 31, 2025 | $256.75M | -43.0% | -19.0% |
| December 31, 2024 | $316.97M | -36.1% | -10.1% |
| September 30, 2024 | $352.54M | -35.3% | -12.8% |
| June 30, 2024 | $404.47M | — | -10.2% |
| March 31, 2024 | $450.21M | — | -9.3% |
| December 31, 2023 | $496.19M | +16.4% | -8.9% |
- Neumora Therapeutics, Inc. showed a decrease of -39.7% in Total Assets compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s total assets has declined by 55.2% (from $426.23 million to $191.05 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: